BHVN
Price
$13.30
Change
+$0.04 (+0.30%)
Updated
Sep 29, 04:59 PM (EDT)
Capitalization
1.96B
49 days until earnings call
Intraday BUY SELL Signals
PRAX
Price
$281.58
Change
-$4.07 (-1.42%)
Updated
Sep 29, 04:59 PM (EDT)
Capitalization
7.84B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHVN vs PRAX

BHVN vs PRAX Comparison Chart in %
View a ticker or compare two or three
VS
BHVN vs. PRAX commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and PRAX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BHVN vs PRAX: Fundamental Ratings
BHVN
PRAX
OUTLOOK RATING
1..100
5762
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
5935
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRAX's Valuation (72) in the null industry is in the same range as BHVN (90) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to BHVN’s over the last 12 months.

PRAX's Profit vs Risk Rating (100) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to BHVN’s over the last 12 months.

PRAX's SMR Rating (97) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to BHVN’s over the last 12 months.

PRAX's Price Growth Rating (35) in the null industry is in the same range as BHVN (59) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to BHVN’s over the last 12 months.

PRAX's P/E Growth Rating (100) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that PRAX’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNPRAX
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 5 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 28 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (BHVN: $13.27 vs. PRAX: $285.65)
Brand notoriety: BHVN and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 70% vs. PRAX: 104%
Market capitalization -- BHVN: $1.96B vs. PRAX: $7.84B
BHVN [@Biotechnology] is valued at $1.96B. PRAX’s [@Biotechnology] market capitalization is $7.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green while PRAX’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, PRAX is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 5 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).

  • BHVN’s TA Score: 5 bullish, 5 bearish.
  • PRAX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BHVN is a better buy in the short-term than PRAX.

Price Growth

BHVN (@Biotechnology) experienced а -6.68% price change this week, while PRAX (@Biotechnology) price change was -4.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.65%. For the same industry, the average monthly price growth was -7.25%, and the average quarterly price growth was +3.85%.

Reported Earning Dates

BHVN is expected to report earnings on Nov 17, 2026.

PRAX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+0.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BHVN
Daily Signal:
Gain/Loss:
PRAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XBJA34.69-0.04
-0.12%
Innovator U.S. Equity Accelerated 9 Buffer ETF - January (XBJA)
SUSC22.00-0.13
-0.59%
iShares ESG Aware USD Corporate Bond ETF (SUSC)
RFI10.48-0.08
-0.76%
Cohen and Steers Total Return Realty Fund
EBIZ27.68-0.28
-1.02%
Global X E-Commerce ETF (EBIZ)
INDQ25.21-0.57
-2.22%
Pacer ActiveAlpha India Quality ETF (INDQ)

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
+1.73%
BEAM - PRAX
40%
Loosely correlated
-0.16%
ANRO - PRAX
38%
Loosely correlated
+0.64%
BHVN - PRAX
37%
Loosely correlated
+2.16%
RAPP - PRAX
35%
Loosely correlated
-1.39%
VERU - PRAX
35%
Loosely correlated
-0.59%
More